Luye Pharma Group (HKG:2186) reported 312.9 million yuan in attributable profit for the first half of 2025, falling 19% from 387.8 million yuan a year earlier, according to a Hong Kong bourse filing Thursday.
Earnings per share was 0.0832 yuan, compared with 0.1031 yuan in the prior year.
Revenue rose 3.5% year-on-year to 3.18 billion yuan, figures showed.
Shares of the pharma company gained 8.1% in afternoon trade Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.